Skip to main content

Table 2 Patient characteristics

From: Hypersensitivity to oxaliplatin: clinical features and risk factors

Patient characteristics (n = 191) Mean (range) n (%)
Age (years) 62.4 (23–84)  
Sex, male   78 (41)
Atopic diseases   32 (17)
Diagnosis   
Colon   86 (45)
Stomach   10 (5)
Ovary   35 (18)
Pancreas   9 (5)
Peritoneum   8 (4)
Rectum   25 (13)
Other1   18 (10)
Prior platinum exposure, yes   45 (24)
Treament regimen   
FOLFOX4 (oxaliplatin, 5-fluorouracil and leucovorin)   101 (53)
FOLFOX4-bevacizumab   10 (5)
FOLFOX4-cetuximab   4 (2)
GEMOX (oxaliplatin and gemcitabine)   47 (25)
Oxaliplatin alone   5 (3)
TOMOX(oxaliplatin and raltitrexed)   12 (6)
Other2   12 (6)
Total infusion courses 6.4 (1–18)  
Oxaliplatin dose (mg/m2) 85.3 (42–160)  
  1. 1Includes: appendix (2), gallbladder (4), liver (2), mouth (1), oesophagus (2), endometrium (1) and unknown primary (6).
  2. 2Includes: 2 ELOGEM (combination of oxaliplatin and gemcitabine), 2 EOX (combination of oxaliplatin, epirubicin and capecitabine), 2 FOLFIRINOX (combination of oxaliplatin, irinotecan, 5-fluorouracil and leucovorin), 1 FOLFOX6 (combination of oxaliplatin, 5-fluorouracil and leucovorin), 2 FOLFOX7 (combination of oxaliplatin, 5-fluorouracil and leucovorin), 1 patient treated with oxaliplatin and epirubicine, 1 oxaliplatin with cetuximab and 1 XELOX (combination of oxaliplatin and capecitabine).